Abstract
Cytochromes P450 (CYPs) compose a superfamily of similar proteins involved in detoxification and elimination, as well as activation of a wide variety of compounds. Most CYP family members are localized in the liver. In order to assess whether peripheral blood leukocytes (PBL) are available as a surrogate for the determination of CYP gene expression levels in the liver, we compared CYP gene expression levels in PBL with those in liver tissues from patients with hepatocellular carcinoma (HCC). We measured CYP1A1, 1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 2F1, 2J2, 3A4, 3A5, 3A7, 4A11, 4B1 and CYP27 gene expressions in PBL and in the liver by real‐time reverse‐transcription (RT)‐PCR. We could detect expression of CYP1A1, 1A2, P1B1, 2A6, 2B6 and 2E1 genes in PBL and all the genes except for CYP2F1 in the liver. Although gene expression levels within each subfamily were closely correlated within PBL and within the liver, a clear correlation of gene expression levels between PBL and liver tissues was found only for CYP4B1. Although inter‐individual variation of the expression level of each CYP gene was wide, the induced level was proportional to the basal expression level. Therefore, monitoring of CYP gene expression levels in PBL, especially those of CYP4B1, could be available as a biomarker for monitoring of exposure to environmental pollutants and assessing the associated risk. Compared with non‐tumor tissue, HCC tissues tended to show overexpression of multiple CYP genes, indicating that individualized selection and more effective administration of chemotherapeutic agents could perhaps be based on the pattern of CYP overexpression.
Abbreviations:
- CYP
cytochrome P450
- PBL
peripheral blood leukocytes
- HCC
hepatocellular carcinoma
- ICC
intrahepatic cholangiocarcinoma
- BDK
bile duct cancer
- RT‐PCR
reverse transcription‐polymerase chain reaction
- GAPDH
glycerol dehyde‐3‐phosphate dehydrogenase
References
- 1. Omura T. Forty years of cytochrome P450. Biochem Biophys Res Commun 1999; 266: 690–8. [DOI] [PubMed] [Google Scholar]
- 2. Hasler JA, Estabrook R, Murray M, Pikuleva I, Waterman M, Captevila J, Holla V, Helvig C, Falck JR, Farrell G, Kaminsky LS, Spivack SD, Boitier E, Beaune R. Human cytochrome P450. Mol Aspect Med 1999; 20: 1–137. [Google Scholar]
- 3. Werck‐Reichhart D, Feyreisen R. Cytochromes P450: a success story (review). Genome Biol 2000; 1: 1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 1995; 27: 397–417. [DOI] [PubMed] [Google Scholar]
- 5. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29: 413–580. [DOI] [PubMed] [Google Scholar]
- 6. Raucy JL, Schultz ED, Wester MR, Arora S, Johnston DE, Omdahl JL, Carpenter SP. Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol‐mediated changes in hepatic chlorzoxazone activity. Drug Metab Dispos 1997; 25: 1429–35. [PubMed] [Google Scholar]
- 7. Baron JM, Zwadlo‐Klarwasser G, Jugert F, Hamann W, Rubben A, Mukhtar H, Merk HF. Cytochrome P450 1B1: a major P450 isoenzyme in human blood monocytes and macrophage subsets. Biochem Pharmacol 1998; 56: 1105–10. [DOI] [PubMed] [Google Scholar]
- 8. Lin JH, Lu AY. Inhibition and induction of Cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361–90. [DOI] [PubMed] [Google Scholar]
- 9. Nishimura M, Yoshitsugu H, Naito S, Hiraoka I. Evaluation of gene induction of drug‐metabolizing enzymes and transporters in primary culture of human hepatocytes using high‐sensitivity real‐time reverse transcription PCR. Yakugaku Zasshi 2002; 122: 339–361. [DOI] [PubMed] [Google Scholar]
- 10. Iwata H, Fujita K, Kushida H, Suzuki A, Konno Y, Nakamura K, Fujino A, Kamataki T. High catalytic activity of human Cytochrome P450 co‐expressed with human NADPH‐cytochrome P450 reductase in Escherichia coli. Biochem. Pharmacol 1998; 55: 1315–25. [DOI] [PubMed] [Google Scholar]
- 11. Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y, Funae Y. Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol 1996; 51: 1041–50. [DOI] [PubMed] [Google Scholar]
- 12. Rodriguez‐Antona C, Donato MT, Boobis A, Edwards BJ, Watts PS, Castell JV, Gomez‐Lechon MJ. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002; 32: 505–20. [DOI] [PubMed] [Google Scholar]
- 13. George J, Byth K, Farrell GC. Influence of clinicopathological variables on CYP protein expression in human liver. J Gastroenterol Hepatol 1996; 11: 33–9. [DOI] [PubMed] [Google Scholar]
- 14. Kennedy JM, Riji AM. Effects of surgery on the pharmacokinetic parameters of drugs. Clin Pharmacokinet 1998; 35: 293–312. [DOI] [PubMed] [Google Scholar]
- 15. Piscaglia F, Knittel T, Kobold D, Barnikol‐Watanabe S, Di Rocco P, Ramadori G. Cellular localization of hepatic Cytochrome 1B1 expression and its regulation by aromatic hydrocarbons and inflammatory cytokines. Biochem. Pharmacol 1999; 58: 157–65. [DOI] [PubMed] [Google Scholar]
- 16. Murray GI. The role of Cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol 2000; 192: 419–26. [DOI] [PubMed] [Google Scholar]
- 17. Jounaidi Y, Bonfils C, Perin F, Negishi M, Lange R. Overexpression of a cytochrome P‐450 of the 2a family (CYP2a‐5) in chemically induced hepato‐mas from female mice. Eur J Biochem. 1994; 219: 791–98. [DOI] [PubMed] [Google Scholar]
- 18. Raunio H, Hakkola J, Hukkanen J, Pelkonen O, Edwards R, Boobis A, Anttila S. Expression of xenobiotic‐metabolizing Cytochrome P450s in human pulmonary tissues. Arch Toxicol Suppl 1998; 20: 465–9. [DOI] [PubMed] [Google Scholar]
- 19. Janardan SK, Lown KS, Schmiedlin‐Ren P, Thummel KE, Watkins PB. Selective expression of CYP3A5 and not CYP3A4 in human blood, Pharmacogenetics 1996; 6: 379–85. [DOI] [PubMed] [Google Scholar]
- 20. Nakamoto T, Hase I, Imaoka S, Hiroi T, Oda Y, Asada A, Funae Y. Quantitative RT‐PCR for CYP3A4 mRNA in human peripheral lymphocytes: induction of CYP3A4 in lymphocytes and in liver by rifampicin. Pharmacogenetics 2000; 10: 571–5. [DOI] [PubMed] [Google Scholar]
- 21. Asghar A, Gorski JC, Haehner‐Daniels B, Hall SD. Induction of multidrug resistance‐1 and Cytochrome P450 mRNAs in human mononuclear cells by rifampin, Drug Metab Dispos 2002; 30: 20–6. [DOI] [PubMed] [Google Scholar]
- 22. Muhlenfeld K, Langner A. Cytochrome P450 1A1 and 4A activities in isolated rat spleen lymphocytes. Pharmazie 2001; 56: 329–31. [PubMed] [Google Scholar]
- 23. Bonazzi A, Mastyugin V, Mieyal PA, Dunn MW, Laniado‐Schwartzman M. Regulation of cyclooxygenase‐2 by hypoxia and peroxisome proliferators in the corneal epithelium. J Biol Chem. 2000; 275: 2837–44. [DOI] [PubMed] [Google Scholar]
- 24. Vafeas C, Mieyal PA, Urbano F, Falck JR, Chauhan K, Berman M, Schwartzman ML. Hypoxia stimulates the synthesis of Cytochrome P450‐derived inflammatory eicosanoids in rabbit corneal epithelium. J Pharmacol Exp Ther 1998; 287: 903–10. [PubMed] [Google Scholar]
- 25. Verscholyle RD, Philpot RM, Wolf CR, Dinsdale D. CYP4B1 activates 4‐ipomeanol in rat lung. Toxicol Appl Pharmacol 1993; 123: 193–8. [DOI] [PubMed] [Google Scholar]
- 26. Finnstrom N, Ask B, Dahl ML, Gadd M, Rane A. Intra‐individual variation and sex differences in gene expression of cytochromes P450 in circulating leukocytes. Pharmacogenomics J 2002; 2: 111–6. [DOI] [PubMed] [Google Scholar]